TD Cowen Issues Pessimistic Forecast for Abbott Laboratories (NYSE:ABT) Stock Price

Key Points

• TD Cowen cut Abbott’s price target from $135 to $118 but maintained a “buy” rating, implying roughly 17% upside; the analyst consensus remains “Moderate Buy” with a $117.92 target.
• Abbott reported quarterly EPS of $1.42, matching estimates, while revenue of $13.01 billion slightly exceeded forecasts and rose 14.5% year over year.
• Near-term concerns remain: Abbott lowered its sales-growth outlook because of weakness in medical devices and plans to spin off its approximately $8.5 billion Nutrition business by the end of 2027.

Abbott Laboratories (NYSE:ABT - Get Free Report) had its target price reduced by stock analysts at TD Cowen from $135.00 to $118.00 in a research report issued on Thursday, Benzinga reports. The brokerage currently has a "buy" rating on the healthcare product maker's stock. TD Cowen's price target would indicate a potential upside of 17.04% from the stock's previous close.

Several other equities analysts also recently commented on the company. Wolfe Research upgraded Abbott Laboratories from a "peer perform" rating to an "outperform" rating and set a $130.00 target price for the company in a research report on Thursday, August 13th. Wells Fargo & Company increased their price objective on Abbott Laboratories from $109.00 to $112.00 and gave the stock an "overweight" rating in a research note on Friday, July 17th. Weiss Ratings upgraded Abbott Laboratories from a "hold (c-)" rating to a "hold (c)" rating in a research note on Friday, September 18th. JPMorgan Chase & Co. lifted their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the company an "overweight" rating in a report on Friday, July 17th. Finally, BTIG Research reduced their target price on shares of Abbott Laboratories from $134.00 to $125.00 and set a "buy" rating on the stock in a research note on Thursday. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, Abbott Laboratories presently has a consensus rating of "Moderate Buy" and a consensus price target of $117.92.

Abbott Laboratories Stock Performance

ABT opened at $100.82 on Thursday. The stock's 50 day simple moving average is $105.47 and its 200-day simple moving average is $98.28. The company has a current ratio of 1.38, a quick ratio of 0.97 and a debt-to-equity ratio of 0.57. The stock has a market cap of $174.46 billion, a PE ratio of 32.58, a P/E/G ratio of 1.90 and a beta of 0.59. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $132.02.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its quarterly earnings results on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share for the quarter, hitting analysts' consensus estimates of $1.42. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $13.01 billion for the quarter, compared to the consensus estimate of $12.99 billion. During the same quarter in the previous year, the company earned $1.30 earnings per share. The business's revenue was up 14.5% compared to the same quarter last year. Sell-side analysts forecast that Abbott Laboratories will post 5.53 EPS for the current year.

Hedge Funds Weigh In On Abbott Laboratories

Several institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. raised its stake in shares of Abbott Laboratories by 4.6% in the 2nd quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker's stock valued at $13,843,610,000 after purchasing an additional 6,769,518 shares during the period. State Street Corp grew its holdings in shares of Abbott Laboratories by 1.7% during the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker's stock worth $7,343,246,000 after buying an additional 1,350,766 shares in the last quarter. Bank of America Corp DE acquired a new stake in Abbott Laboratories in the 2nd quarter valued at approximately $1,603,607,000. Deutsche Bank AG lifted its stake in Abbott Laboratories by 18.6% in the 2nd quarter. Deutsche Bank AG now owns 16,706,669 shares of the healthcare product maker's stock valued at $1,515,963,000 after acquiring an additional 2,614,965 shares in the last quarter. Finally, Legal & General Group Plc acquired a new position in Abbott Laboratories during the 2nd quarter worth approximately $1,082,524,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories News Summary

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott reported third-quarter adjusted earnings of $1.42 per share, in line with the broader consensus, while revenue of $13.01 billion slightly exceeded the $12.99 billion estimate. Reported sales increased 14.5% year over year, and comparable sales rose 7%. Abbott Reports Third-Quarter 2026 Results
• Positive Sentiment: The company reaffirmed its full-year adjusted EPS guidance, while highlighting new product approvals and margin expansion. The results also showed year-over-year EPS growth from $1.30 to $1.42. Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
• Positive Sentiment: Robert W. Baird raised its ABT price target from $121 to $123 and maintained an “outperform” rating. BTIG lowered its target from $134 to $125 but retained a “buy” rating; both targets imply substantial upside from the reference price. Benzinga Analyst Actions
• Neutral Sentiment: Abbott intends to execute a tax-free spin-off of its approximately $8.5 billion Nutrition business, including Similac, Ensure and Pedialyte, by the end of 2027. Management expects the separation to sharpen strategic focus and improve Abbott’s growth and margin profile, but investors must assess execution and the eventual standalone businesses. Abbott Nutrition Spin-Off Announcement
• Negative Sentiment: Abbott reduced its 2026 sales-growth forecast, citing weakness in medical devices. That outlook revision overshadowed the revenue beat and raised concerns about near-term momentum. Abbott Lowers 2026 Sales Growth Forecast
• Negative Sentiment: Some analysts characterized adjusted EPS as a modest miss against a $1.43 estimate, adding to the cautious reaction. The Nutrition separation also introduced uncertainty and contributed to selling pressure despite strong headline growth. ABT Stock Down After Third-Quarter Results

About Abbott Laboratories

Abbott Laboratories is a global healthcare company that develops, manufactures and markets a broad range of medical products and services. Founded in 1888 by Wallace C. Abbott, the company is headquartered in Abbott Park, Illinois, and serves patients, healthcare providers and consumers in markets around the world.

Abbott operates across four principal businesses: medical devices, diagnostics, nutrition and established pharmaceutical products. Its offerings include glucose-monitoring systems such as FreeStyle Libre; cardiovascular devices, including stents and structural heart products; laboratory and point-of-care diagnostic systems; and branded generic medicines in areas such as gastroenterology, women's health and cardiometabolic care.

The company's nutrition portfolio includes infant and pediatric products such as Similac and PediaSure, adult nutritional products such as Ensure, and rehydration products such as Pedialyte.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.